Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories

Ping Qiu1, Ling Pang2, Gladys Arreaza3

  • 1Translational Molecular Biomarkers, Merck Research Laboratories, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, NJ 07065, USA. ping.qiu@merck.com.

Summary

Whole exome sequencing (WES) data from different vendors can be combined for accurate tumor mutational burden analysis. This standardization is crucial for guiding cancer treatment with immune checkpoint inhibitors.